COMPASS Pathways (CMPS) Receives a Buy from Oppenheimer

In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on COMPASS Pathways (CMPS – Research Report), with a price target of $25.00. The company’s shares closed yesterday at $8.54.

According to TipRanks, Brisebois is an analyst with an average return of -3.4% and a 35.59% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Dyne Therapeutics, Avadel Pharmaceuticals, and Aldeyra Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for COMPASS Pathways with a $45.00 average price target, implying a 426.93% upside from current levels. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $50.00 price target.

The company has a one-year high of $12.75 and a one-year low of $5.01. Currently, COMPASS Pathways has an average volume of 644.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

COMPASS Pathways (CMPS) Company Description:

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.